Metachronous and Clonally Related Classic Hodgkin Lymphoma and Nodular Lymphocyte Predominant Hodgkin Lymphoma
Yi Ding,Andrew Campbell,Xuan Zhang,Kai Fu,Ji Yuan
DOI: https://doi.org/10.1016/j.pathol.2020.06.019
IF: 5.335
2021-01-01
Pathology
Abstract:Classic Hodgkin lymphoma (CHL) and nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) are two distinct subtypes of Hodgkin lymphoma by the World Health Organization (WHO) classification.1Swerdlow S.H. Campo E. Harris N.L. et al.WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues..Revised 4th ed. Internation Agency for Research on Cancer, Lyon2017: 424Google Scholar They share some common clinical and pathological features, but are different in immunophenotype, inflammatory background, and genetic characteristics. The coexistence of CHL and NLPHL in the same patient is exceedingly rare.2Gelb A.B. Dorfman R.F. Warnke R.A. Coexistence of nodular lymphocyte predominance Hodgkin's disease and Hodgkin's disease of the usual type.Am J Surg Pathol. 1993; 17: 364-374Crossref PubMed Scopus (10) Google Scholar We present a case of CHL where complete remission was achieved after treatment, but clonally related NLPHL developed subsequently. A previously healthy 14-year-old male presented with generalised lymphadenopathy. He had no B symptoms. His uncle had a history of CHL. The computed tomography (CT) scan revealed lymphadenopathy in the left neck, bilateral supraclavicular, left axilla, anterior mediastinum and right hilum, and multiple low attenuating lesions in the spleen. The positron emission tomography (PET) scan confirmed glucose avid lymphadenopathy of these areas with a maximum SUV of 16.1 at right hilum. An excisional biopsy of left supraclavicular lymph node showed a nodular infiltrate dissected by thick fibrotic bands (Fig. 1A). The infiltrate was composed of scattered large Hodgkin/Reed–Sternberg (HRS) cells in a background of small lymphocytes, eosinophils, histiocytes, and plasma cells (Fig. 1B). The HRS cells were positive for PAX5 (weak), CD15 and CD30, and negative for CD20, CD45 and EMA (Fig. 1C–F). In situ hybridisation for EBV encoded small RNA (EBER) was negative. The findings were consistent with nodular sclerosis CHL. The cytogenetic analysis revealed a complex karyotype with an abnormal hypertriploid clone characterised by additional unknown material on Xq, 1q, 2p, and 7q, isochromsomes of 7p and 10q, gain of 1, 2, 10, 19, and 5-6 marker chromosomes and loss of 6 and 17 {78–79,XY,add(X)(q?24),+1,add(1)(q32)x2,+2,add(2)(p16)x2,-6,+add(7)(q31)x2,i(7)(p10), +10,?i(10)(q10)x2,-17,+19,+5-6mar[5]/46,XY[10]}. The patient's bone marrow was not involved by the CHL. He was designated stage IIIAS CHL and was treated per Children's Oncology Group (COG) protocol AHOD0031 for intermediate risk Hodgkin disease. He received four cycles of ABVE-PC (adriamycin, bleomycin, vincristine sulfate, etoposide, prednisone and cyclophosphamide). Post-chemotherapy the CT scan showed resolution of lymphadenopathy and splenic mass. The PET scan showed no convincing evidence of residual lymphoma. He subsequently received radiation therapy of 2100 cGy to the neck, mediastinum and spleen. He was in clinical remission. Fifty-two months later, he developed left cervical lymphadenopathy (2.7×1.9 cm), which was incidentally found by a CT scan. A subsequent PET scan revealed markedly hypermetabolic left cervical lymphadenopathy with a maximum SUV of 17.5. Examination of the abdomen and pelvis showed normal uptake. He denied any B symptoms. The biopsy of this lymph node revealed a vaguely nodular infiltrate effacing the normal architecture of lymph node (Fig. 1G). The nodules contained small lymphocytes admixed with scattered, large lymphocyte predominant (LP) cells (Fig. 1H). Eosinophils were absent. The LP cells were positive for CD20, CD79a, PAX5, partial CD30, CD45, BCL6, EMA, and IgD, but negative for CD15 and MUM1 (Fig. 1I–K). CD21 highlighted expanded follicular dendritic meshworks. Characteristic LP cells rosetting by small T cells were highlighted by CD3 and PD1 immunostains (Fig. 1L). The background cells in the nodules were predominantly small B-cells. EBER in situ hybridisation was negative. These features were consistent with NLPHL. There was no cytogenetic evidence of an abnormal clone. The patient's bone marrow was again negative for lymphoma involvement. He was treated with two cycles of ICE (ifosfamide, carboplatin and etoposide) chemotherapy. A follow-up PET scan showed resolution of hypermetabolic activity in cervical node. He underwent autologous peripheral blood stem cell transplant after consolidation with BEAM (carmustine, etoposide, cytarabine, and melphalan). He received rituximab on day +30 post-transplant and completed 16 days of involved field radiotherapy (total 30.6 Gy) on day +60 post-transplant. Currently he has remained disease free for 93 months post-transplantation. Next generation sequencing (NGS) was used to analyse the IGK gene rearrangement on the DNA extracted from tissue of CHL and NLPHL. DNA was amplified according to the manufacturer instructions using the LymphoTrack IGK Assay Panels (Invivoscribe Technologies, USA). PCR amplicons were quantified using the KAPA library quantification kit (Hoffman-La Roche, Switzerland). The barcoded IGK libraries were pooled and sequenced on the MiSeq Dx using the MiSeq Reagent Kit v3 (Illumina, USA). The sequencing data were analysed using the LymphoTrack Software MiSeq v2.11 package (Invivoscribe Technologies). The merged reads (1 or 2 nucleotides difference) were used to determine clonality for the IGK assay. If the percentage of total reads for a merged IGK sequence was higher than 2% and four-fold greater than the tenth most common merged sequence, it was designated as a clonal population. The same clonal IGK rearrangement (V3D-20 J1) was identified from both samples with identical sequences (Fig. 2), which supported that these two tumours were clonally related. CHL and NLPHL account for 90% and 10% of Hodgkin lymphoma, respectively.1Swerdlow S.H. Campo E. Harris N.L. et al.WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues..Revised 4th ed. Internation Agency for Research on Cancer, Lyon2017: 424Google Scholar It is extremely rare that CHL and NLPHL occur in the same patient. In the study from Stanford, five patients were found to have both CHL and NLPHL simultaneously or consecutively among 4748 diagnoses of Hodgkin disease (including CHL and NLPHL) between 1980 and 1992.2Gelb A.B. Dorfman R.F. Warnke R.A. Coexistence of nodular lymphocyte predominance Hodgkin's disease and Hodgkin's disease of the usual type.Am J Surg Pathol. 1993; 17: 364-374Crossref PubMed Scopus (10) Google Scholar We performed an English literature search for the reported cases in PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) using different combinations of key words in the title/abstract field, including ‘composite/coexist/metachronous lymphoma, Hodgkin disease/lymphoma, nodular lymphocyte predominant Hodgkin lymphoma.’ A total of nine cases have been reported in the literature, including six metachronous cases, two patients with composite lymphoma, and one synchronous case but at different sites (Table 1).2Gelb A.B. Dorfman R.F. Warnke R.A. Coexistence of nodular lymphocyte predominance Hodgkin's disease and Hodgkin's disease of the usual type.Am J Surg Pathol. 1993; 17: 364-374Crossref PubMed Scopus (10) Google Scholar, 3Song J.Y. Eberle F.C. Xi L. et al.Coexisting and clonally identical classic hodgkin lymphoma and nodular lymphocyte predominant hodgkin lymphoma.Am J Surg Pathol. 2011; 35: 767-772Crossref PubMed Scopus (16) Google Scholar, 4Miettinen M. Franssila K.O. Saxen E. Hodgkin's disease, lymphocytic predominance nodular. Increased risk for subsequent non-Hodgkin's lymphomas.Cancer. 1983; 51: 2293-2300Crossref PubMed Scopus (133) Google Scholar, 5Szczepanowski M. Masque-Soler N. Oschlies I. et al.Composite lymphoma of nodular lymphocyte-predominant and classical Hodgkin lymphoma-Epstein-Barr virus association suggests divergent pathogenesis despite clonal relatedness.Hum Pathol. 2013; 44: 1434-1439Crossref PubMed Scopus (14) Google Scholar All the cases were young to middle aged male patients, ranging from 10–48 years with a median age of 22 years. Among seven patients with the initial staging information, three presented with localised lymphadenopathy (stage I) and four with advanced stage disease (stage III). The bone marrow was spared in all patients. Three patients developed NLPHL preceding CHL, whereas four had CHL before NLPHL. Among seven metachronous cases, the average time interval to develop the second lymphoma was 9.5 years. Mixed cellularity CHL and nodular sclerosis CHL each comprised 50% of the cases. A clonal IGK or IGH gene rearrangement was found on the cases with coexistence of CHL and NLPHL (Cases 8 and 9), but clonal relationship was not investigated on other reported metachronous cases. Herein, we showed a clonal relationship between CHL and NLPHL in a metachronous case. The presence of both entities in a same patient and a clonal relationship suggest HRS and LP cells can derive from a common B-cell precursor.Table 1A review of coexisting CHL and NLPHL casesCaseTypeAge/SexFirst Bx site/DxBMInitial stageTherapyResponseSecond Bx site/DxTime interval (years)Clonal relationshipLMP/EBERStatus/follow up (years)Reference1Metachronous21/MLN: NLPHLN/AN/AN/AN/ASpleen: CHL,MC5NDN/AAlive/642Metachronous17/MLN: NLPHLNegIARoentgen therapyN/ALN (same site): CHL,MC17NDN/ADead/1943Metachronous10/MLN: CHL, MCNegIA/IBXRT+ChemoCRLN (diff. site) NLPHL18NDLMP/–N/A24Metachronous30/MLN: CHL, NSNegIIIASAuto BMTN/ALN (same site): NLPHL10NDLMP/–Dead/1125Metachronous22/MLN: CHL, NSNegIIIASABVDPRLN (diff. site): NLPHL5NDLMP/–N/A26Metachronous27/MLN: NLPHLN/AN/AAdriamycin, vinblastine sulfate, VP16PRLN (same site): CHL,NS3NDLMP/–N/A27Composite22/MLN: CHL,MC + NLPHLNegIA/IBXRTCRNANANDNDN/A28Synchronous24/MThymic mass: CHL,NSParotid mass: NLPHLNegN/AN/AN/ANANAClonally relatedEBER/both –N/A39Composite48/MLN:CHL,MC + NLPHLNegIIIAABVD+ XRT+BEACOPPCRNANAClonally relatedEBERCHL/+NLPHL/–Alive/1.8510Metachronous14/MLN: CHL, NSNegIIIASABVE-PC+ XRTCRLN (diff. site) NLPHL4.3Clonally relatedEBER/both –Alive/7.8Current caseABVD, adriamycin, bleomycin, vinblastine sulfate, dacarbazine; ABVE-PC, adriamycin, bleomycin, vincristine sulfate, etoposide, prednisone and cyclophosphamide; BEACOPP, cyclophosphamide, doxorubicin, etoposide phosphate, natulan, vincristine, bleomycin; BMT, bone marrow transplant; Bx, biopsy; Chemo, chemotherapy; CHL, classic Hodgkin lymphoma; CR, complete remission; diff, different; Dx, diagnosis; EBER, EBV-encoded RNA; F, female; LMP, latent membrane protein; LN, lymph node; M, male; MC, mixed-cellularity; NA, not applicable; N/A, not available; ND, not done; Neg, negative; NLPHL, nodular lymphocyte predominant Hodgkin lymphoma; NS, nodular sclerosis; PR, partial remission; XRT, radiotherapy. Open table in a new tab ABVD, adriamycin, bleomycin, vinblastine sulfate, dacarbazine; ABVE-PC, adriamycin, bleomycin, vincristine sulfate, etoposide, prednisone and cyclophosphamide; BEACOPP, cyclophosphamide, doxorubicin, etoposide phosphate, natulan, vincristine, bleomycin; BMT, bone marrow transplant; Bx, biopsy; Chemo, chemotherapy; CHL, classic Hodgkin lymphoma; CR, complete remission; diff, different; Dx, diagnosis; EBER, EBV-encoded RNA; F, female; LMP, latent membrane protein; LN, lymph node; M, male; MC, mixed-cellularity; NA, not applicable; N/A, not available; ND, not done; Neg, negative; NLPHL, nodular lymphocyte predominant Hodgkin lymphoma; NS, nodular sclerosis; PR, partial remission; XRT, radiotherapy. CHL in a first degree relative is associated with an increased risk of developing CHL and other lymphoproliferative diseases, and a male predominance was found in familial HL cases.6Bernard S.M. Cartwright R.A. Darwin C.M. et al.Hodgkin's disease: case control epidemiological study in Yorkshire.Br J Cancer. 1987; 55: 85-90Crossref PubMed Scopus (94) Google Scholar, 7Kerzin-Storrar L. Faed M.J. MacGillivray J.B. et al.Incidence of familial Hodgkin's disease.Br J Cancer. 1983; 47: 707-712Crossref PubMed Scopus (47) Google Scholar, 8Goldin L.R. Pfeiffer R.M. Gridley G. et al.Familial aggregation of Hodgkin lymphoma and related tumors.Cancer. 2004; 100: 1902-1908Crossref PubMed Scopus (140) Google Scholar The father and paternal first and third cousins of Case 8 all had CHL; his paternal grandfather and the first cousin had acute leukaemia.3Song J.Y. Eberle F.C. Xi L. et al.Coexisting and clonally identical classic hodgkin lymphoma and nodular lymphocyte predominant hodgkin lymphoma.Am J Surg Pathol. 2011; 35: 767-772Crossref PubMed Scopus (16) Google Scholar Our patient's uncle had a history of CHL. Both cases suggest a genetic component in HL development. NGS was used to analyse the IGK gene rearrangements in our study. The advantages of using NGS over traditional polymerase chain reaction (PCR) based IGH/IGK clonality assay include enhanced sensitivity, specificity, and objectivity, and allowing investigators to monitor and track clonal evolution through the entire course of the disease. Microdissection of HRS or LP cells is not required for NGS based IGK assay. The percentages of total reads of identical IGK sequence detected in CHL and NLPHL were 3.7% and 3.9%, comparable to the low percentages of Hodgkin cells in the specimens. Our patient illustrates a rare case of metachronous, clonally related CHL and NLPHL. It is challenging for pathologists to diagnose, as well as for clinicians to treat such patients, especially cases with concurrent composite Hodgkin lymphoma. Limited tissue such as needle core biopsy can be problematic and a large excision is generally required for a diagnosis of such cases. Given the unpredictable nature of recurrent disease, biopsy of the relapsed lesion is essential for diagnosis and treatment purposes. Conflicts of interest and sources of funding: The authors state that there are no conflicts of interest to disclose.